Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Advanced Gastric Cancer
A new phase 2 study in Japan and South Korea will evaluate the efficacy and safety of DS-8201 in ER2-expressing gastric cancer.
Read Source